Shionogi

Japan - OsakaBiotechnology2 H-1B visas (FY2023)

Focus: Shionogi is a 145-year-old Japanese pharmaceutical company headquartered in Osaka, specializing in small-molecule therapeutics focused on infectious diseases. The company is heavily concentrated on its flagship antibiotic FETROJA, which represents 100% of reported revenue.

Infectious Diseases

Profile data last refreshed 16h ago · AI intelligence enriched 1w ago

Open Jobs

30+202 this month

Hot — 223 jobs added in 30d

Net +202 (223 new, 21 removed). Aggressive expansion phase.

Should You Work at Shionogi?

AI assessment

Shionogi is a stabilizing infectious-disease specialist for 3–5 years but carries high long-term restructuring risk; best suited for commercial or regulatory professionals seeking near-term revenue-stage execution, not pipeline longevity.

Why Work Here

Established 1878 Japanese pharma with deep infectious-disease expertise and a peaked revenue driver (FETROJA) providing financial stability through 2035 patent exclusivity

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

Slowing

Jobs decreasing

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

FETROJA

Gram-negative bacterial infections

$4M Part D

Peak9.0yr

Sole revenue driver accounting for 100% of company income; niche antibiotic for resistant gram-negative infections with 11-year patent runway.

Help build intelligence for Shionogi

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Active hiring across 37 roles, with commercial (12) and regulatory (3) departments expanding—signaling launch readiness for pipeline assets like XOCOVA (ensitrelvir)

Phase 3-stage pipeline including influenza (Baloxavir Marboxil) and HIV programs (Dolutegravir) offers mid-career exposure to registration-stage development and early commercial scale

Watch Out For

100% revenue concentration in a single antibiotic creates severe restructuring risk post-2035 LOE; pipeline is shallow (2 Phase 3 programs, 20 total active trials) with no breakthrough candidates visible
Limited H1B sponsorship (2 approvals in 2023) and Japan-based headquarters suggest constrained US hiring and potential visa barriers for non-Japanese nationals

Generated by Claude from Shionogi's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

XOCOVA

Influenza

Launch15.6yr

Recently launched antiviral targeting pandemic preparedness; long LOE window (2042) offers multi-decade upside if adoption accelerates post-launch.

DORIBAX

Bacterial infections

LOE Approaching

Carbapenem approaching loss of exclusivity; commercial decline expected as generic entry accelerates.

COGNEX

Alzheimer's disease

LOE Approaching

Hepatotoxic early-era Alzheimer's agent with minimal modern clinical use; legacy asset in managed decline.

RYBIX ODT

Chronic pain

LOE Approaching

Opioid formulation facing regulatory and prescriber headwinds in an opioid-constrained market; post-LOE erosion likely.

ULESFIA

Pediculosis

LOE Approaching

Niche topical antiparasitic with limited market size and approaching generic competition.

UROPLUS SS

Urinary tract infection

Pre-Launch

ANDA filing for combination antibacterial; launch expected to support urology franchise growth.

UROBAK

Urinary tract infection

Pre-Launch

ANDA filing for urinary antiseptic; pre-launch status indicates near-term commercial opportunity in UTI space.

UROPLUS DS

Urinary tract infection

Pre-Launch

ANDA formulation variant; part of multi-SKU urology portfolio strategy to capture market share.

Products & Portfolio (2)

7 discontinued, 0 duplicate formulations not shown

Key Products by Revenue

FETROJA

cefiderocol sulfate tosylate

Other Products (1)

XOCOVA

ensitrelvir

Launch

SMORAL · TABLET

2026

LOE: 2042

Pipeline & Clinical Trials

Cetrorelix

Premenopause

N/A

Clinical Trials (1)

NCT00628121Clinical Pharmacological Study of GnRH Antagonist, Cetrorelix for Healthy Female Volunteer

N/A

Women's Satisfaction and Adherence to Vulvovaginal Atrophy Treatments

Vulvovaginal Atrophy

N/A

Clinical Trials (1)

NCT04607707Women's Satisfaction and Adherence to Vulvovaginal Atrophy Treatments

N/A

Cefiderocol

Bacterial Infections

N/A

Clinical Trials (1)

NCT03780140Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections

N/A

NORSPAN Buprenorphine Transdermal Patchs for Very-low dose group

Autism Spectrum Disorder

N/A

Clinical Trials (1)

NCT06772324An Exploratory Clinical Study of a Low-dose Buprenorphine Patch for the Treatment of Autism Spectrum Disorders

N/A

Edaravone

Amyotrophic Lateral Sclerosis

N/A

Clinical Trials (5)

NCT00200356Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke

Phase 4

NCT04577404Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Cefiderocol

Gram-Negative Infection

N/A

Clinical Trials (1)

NCT05789199Use of Cefiderocol in the Management of Gram-Negative Infections

N/A

Baloxavir Marboxil

Healthy Volunteer

N/A

A Study to Investigate How Respiratory Syncytial Virus (RSV) Infection Develops and Changes Over Tim

RSV Infections

N/A

Clinical Trials (1)

NCT06746051A Study to Investigate How Respiratory Syncytial Virus (RSV) Infection Develops and Changes Over Time in Pediatric Participants

N/A

GSK1349572

Healthy Subjects

Phase 1

S-892216-PO

Renal Impairment

Phase 1

Clinical Trials (1)

NCT07217886A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls

Phase 1

BPN14770

Renal Impairment

Phase 1

Clinical Trials (1)

NCT07012005Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls

Phase 1

S-488210

Lung Cancer

Phase 1

Clinical Trials (1)

NCT04316689First-in-human Study of S-588210 (S-488210+S-488211)

Phase 1

Ensitrelvir

Healthy Adult Female Participants

Phase 1

Clinical Trials (1)

NCT06775730A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants

Phase 1

GSK1265744 10 mg oral solution

HIV Infection

Phase 1

S-740792 Suspension

Healthy Participants

Phase 1

Clinical Trials (1)

NCT06724978A Study of S-740792 in Healthy Adult Study Participants

Phase 1

S-888711

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT03897413Effect of Food and Calcium on Pharmacokinetics of a Single Dose of S-888711 in Healthy Adult Volunteers

Phase 1

BPN14770

Hepatic Impairment

Phase 1

Clinical Trials (1)

NCT07018492Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls

Phase 1

Cefiderocol

Bacterial Pneumonia

Phase 1

Clinical Trials (1)

NCT03862040Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia

Phase 1

Xeruborbactam

Bacterial Infections

Phase 1

Clinical Trials (1)

NCT06547554A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants

Phase 1

DTG

Infection, Human Immunodeficiency Virus

Phase 1

S-337395

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT06270511A Study to Investigate Different Formulations of S-337395 in Healthy Adult Participants

Phase 1

Cefiderocol/Xeruborbactam

Bacterial Infections

Phase 1

Clinical Trials (1)

NCT07104162A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment

Phase 1

GSK1349572

Infections, Human Immunodeficiency Virus and Tuberculosis

Phase 1

GSK1349572

Healthy Volunteer

Phase 1

S-309309

Obesity

Phase 1

Clinical Trials (1)

NCT05247970A Study to Assess S-309309 in Healthy and Obese Participants

Phase 1

Dolutegravir 50 mg tablet

Infections, Human Immunodeficiency Virus and Herpesviridae

Phase 1

GSK1349572

Healthy Subjects

Phase 1

GSK1349572

Infection, Human Immunodeficiency Virus

Phase 1

Rosuvastatin

Healthy Participants

Phase 1

Clinical Trials (2)

NCT04481789Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)

Phase 1

NCT07011992A Study to Assess the Effects of BPN14770 on Rosuvastatin

Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg

Infection, Human Immunodeficiency Virus

Phase 1

Dolutegravir 50 mg

Infection, Human Immunodeficiency Virus

Phase 1

[14C]Xeruborbactam

ADME

Phase 1

Clinical Trials (1)

NCT07083817Mass Balance Study of [14C]Xeruborbactam (QPX7728) in Healthy Adult Male Participants

Phase 1

Dolutegravir

Infections, Human Immunodeficiency Virus and Hepatitis

Phase 1

Ortho-Cyclen

Infection, Human Immunodeficiency Virus

Phase 1

Dolutegravir

Infection, Human Immunodeficiency Virus

Phase 1

S-707106

Type 2 Diabetes Mellitus

Phase 1

Clinical Trials (1)

NCT01154348Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus

Phase 1

GSK1349572

Infection, Human Immunodeficiency Virus

Phase 1

GSK1349572

Infections, Human Immunodeficiency Virus and Herpesviridae

Phase 1

Midazolam

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT05395104A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy Participants